Exact Mass: 351.1947

Exact Mass Matches: 351.1947

Found 25 metabolites which its exact mass value is equals to given mass value 351.1947, within given mass tolerance error 4.0E-5 dalton. Try search metabolite list with more accurate mass tolerance error 8.0E-6 dalton.

Tryprostatin B

(3S-trans)-Hexahydro-3-[[2-(3-methyl-2-butenyl)-1H-indol-3-yl]methyl]-pyrrolo[1,2-a]pyrazine-1,4-dione

C21H25N3O2 (351.1947)


A cyclic dipeptide that is brevianamide F (cyclo-L-Trp-L-Pro) substituted at position 2 on the indole ring by a prenyl group. CONFIDENCE Penicillium amphipolaria

   

deoxybrevianamide E

L-Prolyl-2-(1,1-dimethylallyl)-L-tryptophan anhydride

C21H25N3O2 (351.1947)


A cyclic dipeptide that is brevianamide F (cyclo-L-Trp-L-Pro) substituted at position 2 on the indole ring by a 1,1-dimethylallyl group.

   

6-((3-Cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy)-N-methyl-3-pyridinecarboxamide

6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methylpyridine-3-carboxamide

C21H25N3O2 (351.1947)


GSK189254A (GSK189254 free base) is a novel, potent and selective histamine H3 receptor antagonist with pKi values of 9.59-9.90 and 8.51-9.17 for human and rat H3, respectively.

   

2-Amino-6-[2-[3-(3-methoxyphenyl)phenyl]ethyl]-3,6-dimethyl-5H-pyrimidin-4-one

2-amino-6-(2-{3-methoxy-[1,1-biphenyl]-3-yl}ethyl)-3,6-dimethyl-3,4,5,6-tetrahydropyrimidin-4-one

C21H25N3O2 (351.1947)


   
   
   

N,N-Dimethylnaamine D

N,N-Dimethylnaamine D

C21H25N3O2 (351.1947)


   

22N-Tetrahydroalstonin|4-methyl-3,4,4a,5,7,8,13,13b,14,14a-decahydro-indolo[2,3:3,4]pyrido[1,2-b][2,7]naphthyridine-1-carboxylic acid ethyl ester

22N-Tetrahydroalstonin|4-methyl-3,4,4a,5,7,8,13,13b,14,14a-decahydro-indolo[2,3:3,4]pyrido[1,2-b][2,7]naphthyridine-1-carboxylic acid ethyl ester

C21H25N3O2 (351.1947)


   

3-[1-(3-methyl-but-2-enyl)-indol-3-ylmethyl]-hexahydro-pyrrolo[1,2-a]pyrazine-1,4-dione|cyclo(N-prenyl-L-tryptophyl-L-prolyl)|Cyclo-L-prolyl-L-|N-prenyl-cyclo-L-tryptophyl-L-proline

3-[1-(3-methyl-but-2-enyl)-indol-3-ylmethyl]-hexahydro-pyrrolo[1,2-a]pyrazine-1,4-dione|cyclo(N-prenyl-L-tryptophyl-L-prolyl)|Cyclo-L-prolyl-L-|N-prenyl-cyclo-L-tryptophyl-L-proline

C21H25N3O2 (351.1947)


   

4-{2-[3-(2-Furyl)phenyl]ethyl}-6-(3-methylbutoxy)-2-pyrimidinamin e

4-{2-[3-(2-Furyl)phenyl]ethyl}-6-(3-methylbutoxy)-2-pyrimidinamin e

C21H25N3O2 (351.1947)


   

D-Phenylalanyl-N-Benzyl-L-Prolinamide

D-Phenylalanyl-N-Benzyl-L-Prolinamide

C21H25N3O2 (351.1947)


   

(6r)-2-Amino-6-[2-(3-Methoxybiphenyl-3-Yl)ethyl]-3,6-Dimethyl-5,6-Dihydropyrimidin-4(3h)-One

(6r)-2-Amino-6-[2-(3-Methoxybiphenyl-3-Yl)ethyl]-3,6-Dimethyl-5,6-Dihydropyrimidin-4(3h)-One

C21H25N3O2 (351.1947)


   

N-(3-allyl-2-hydroxybenzylidene)-4-[(4-methylphenyl)amino]butanohydrazide

N-(3-allyl-2-hydroxybenzylidene)-4-[(4-methylphenyl)amino]butanohydrazide

C21H25N3O2 (351.1947)


   

N-{4-[4-(2-methylbenzoyl)-1-piperazinyl]phenyl}propanamide

N-{4-[4-(2-methylbenzoyl)-1-piperazinyl]phenyl}propanamide

C21H25N3O2 (351.1947)


   

N,N-bis(2-methoxyethyl)-2-(4-methylphenyl)quinazolin-4-amine

N,N-bis(2-methoxyethyl)-2-(4-methylphenyl)quinazolin-4-amine

C21H25N3O2 (351.1947)


   

N-(9-ethyl-3-carbazolyl)-2-(2-oxolanylmethylamino)acetamide

N-(9-ethyl-3-carbazolyl)-2-(2-oxolanylmethylamino)acetamide

C21H25N3O2 (351.1947)


   

NPY5RA-972

NPY5RA-972

C21H25N3O2 (351.1947)


NPY5RA-972 is an orally active, central nervous system (CNS) penetrating, potent and selective NPY Y5 receptor antagonist that prevents feeding driven by activation of this receptor[1].

   

(3s,8as)-1-hydroxy-3-{[1-(3-methylbut-2-en-1-yl)indol-3-yl]methyl}-3h,6h,7h,8h,8ah-pyrrolo[1,2-a]pyrazin-4-one

(3s,8as)-1-hydroxy-3-{[1-(3-methylbut-2-en-1-yl)indol-3-yl]methyl}-3h,6h,7h,8h,8ah-pyrrolo[1,2-a]pyrazin-4-one

C21H25N3O2 (351.1947)


   

1-hydroxy-3-{[2-(3-methylbut-2-en-1-yl)-1h-indol-3-yl]methyl}-3h,6h,7h,8h,8ah-pyrrolo[1,2-a]pyrazin-4-one

1-hydroxy-3-{[2-(3-methylbut-2-en-1-yl)-1h-indol-3-yl]methyl}-3h,6h,7h,8h,8ah-pyrrolo[1,2-a]pyrazin-4-one

C21H25N3O2 (351.1947)


   

1-hydroxy-3-{[2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methyl}-3h,6h,7h,8h,8ah-pyrrolo[1,2-a]pyrazin-4-one

1-hydroxy-3-{[2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methyl}-3h,6h,7h,8h,8ah-pyrrolo[1,2-a]pyrazin-4-one

C21H25N3O2 (351.1947)


   

(3s,8as)-1-hydroxy-3-{[2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methyl}-3h,6h,7h,8h,8ah-pyrrolo[1,2-a]pyrazin-4-one

(3s,8as)-1-hydroxy-3-{[2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methyl}-3h,6h,7h,8h,8ah-pyrrolo[1,2-a]pyrazin-4-one

C21H25N3O2 (351.1947)


   

4,5-bis[(4-methoxyphenyl)methyl]-1,3-dimethylimidazol-2-imine

4,5-bis[(4-methoxyphenyl)methyl]-1,3-dimethylimidazol-2-imine

C21H25N3O2 (351.1947)


   

1-hydroxy-3-{[1-(3-methylbut-2-en-1-yl)indol-3-yl]methyl}-3h,6h,7h,8h,8ah-pyrrolo[1,2-a]pyrazin-4-one

1-hydroxy-3-{[1-(3-methylbut-2-en-1-yl)indol-3-yl]methyl}-3h,6h,7h,8h,8ah-pyrrolo[1,2-a]pyrazin-4-one

C21H25N3O2 (351.1947)


   

(3s,8as)-1-hydroxy-3-{[2-(3-methylbut-2-en-1-yl)-1h-indol-3-yl]methyl}-3h,6h,7h,8h,8ah-pyrrolo[1,2-a]pyrazin-4-one

(3s,8as)-1-hydroxy-3-{[2-(3-methylbut-2-en-1-yl)-1h-indol-3-yl]methyl}-3h,6h,7h,8h,8ah-pyrrolo[1,2-a]pyrazin-4-one

C21H25N3O2 (351.1947)


   

(3s,8as)-1-hydroxy-3-({2-[(2r)-3-methylbut-3-en-2-yl]-1h-indol-3-yl}methyl)-3h,6h,7h,8h,8ah-pyrrolo[1,2-a]pyrazin-4-one

(3s,8as)-1-hydroxy-3-({2-[(2r)-3-methylbut-3-en-2-yl]-1h-indol-3-yl}methyl)-3h,6h,7h,8h,8ah-pyrrolo[1,2-a]pyrazin-4-one

C21H25N3O2 (351.1947)